← Eichor
Study identifier: NCT05978193 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Radiotherapy Combined With Immunochemotherapy in Metastatic Esophageal Squamous Cell Carcinoma

Condition: Esophageal Squamous Cell Carcinoma · Esophageal Cancer · Metastatic Esophageal Squamous Cell Carcinoma  ·  Sponsor: Shanghai Chest Hospital

PhasePhase 2
Planned participants100
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

SCR-ESCC-01 is a multicenter, randomized, phase II study aiming to investigate the benefit of early involvement of low-dose radiotherapy(LDRT) and conventionally fractionated radiotherapy(CFRT) in the first-line anti-PD-1 based treatment of metastatic ESCC. It begins with a safety run-in phase, followed by a randomized controlled comparison against standard immunochemotherapy.

This description comes directly from the study's public registry record.

Talk to the study team

Wen Yu, M.D  ·  021-22200000-3203  ·  yuzhiwen0827@163.com

Always discuss trial participation with your own doctor first.

Locations (2)

Shanghai Ruijin HospitalShanghai, ChinaRecruiting
Shanghai Chest HospitalShanghai, ChinaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05978193